Gastroenterology Market – Global Forecast Report 2025–2034

The global gastroenterology market is witnessing substantial growth due to the increasing prevalence of gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS), Crohn’s disease, gastroesophageal reflux disease (GERD), and colorectal cancer. With the rising geriatric population and changes in dietary habits leading to digestive issues, the demand for gastroenterology treatments and diagnostics is surging. Advancements in pharmaceuticals, endoscopic procedures, and personalized medicine are further enhancing market potential. Additionally, the growing awareness regarding gut health and early disease detection is contributing to the rapid expansion of the gastroenterology sector globally.

Gastroenterology Market Size

The global gastroenterology market reached a value of USD 54.59 billion in 2024, driven by the growing incidence of gastrointestinal diseases and technological advancements in diagnostics and therapeutics. The market is projected to expand at a CAGR of 6.2% from 2025 to 2034, reaching an estimated value of USD 93.80 billion by 2034. The increasing investments in medical research and development, along with the demand for non-invasive diagnostic techniques, are expected to propel the market’s growth over the forecast period.

Gastroenterology Market Share

The market share is dominated by leading pharmaceutical and medical device companies such as Abbott Laboratories, Johnson & Johnson, and AbbVie Inc. North America holds the largest market share due to the high prevalence of GI disorders and advanced healthcare infrastructure. Europe follows closely, benefiting from increased government funding for digestive health research. The Asia-Pacific region is emerging as a lucrative market due to rising healthcare expenditures, increasing cases of digestive diseases, and growing awareness about gastrointestinal disorders.

Gastroenterology Market Trends

1. Rising GI Disorder Prevalence – The increasing incidence of GERD, IBS, and inflammatory bowel disease (IBD) is driving market demand.

2. Technological Advancements – Innovations in endoscopy, AI-based diagnostics, and robotic-assisted surgeries are transforming the market.

3. Growing Adoption of Biologics – Biologic drugs for treating Crohn’s disease and ulcerative colitis are gaining traction.

4. Personalized Medicine Growth – Tailored treatments based on genetic and microbiome analysis are revolutionizing gastroenterology care.

5. Expansion in Emerging Markets – Rapid urbanization and lifestyle changes are increasing GI disorders in developing nations, spurring market expansion.

Gastroenterology Market Analysis

The gastroenterology market is expanding due to several critical factors, including the rising burden of digestive diseases, increasing healthcare spending, and technological progress in diagnostics and treatments. Minimally invasive endoscopic procedures are becoming more popular, reducing patient recovery time and hospital stays. Additionally, growing collaborations between biotech companies and research institutions are fostering the development of advanced treatments. However, challenges such as high treatment costs, stringent regulatory requirements, and the limited availability of specialized professionals may hinder market growth. The ongoing research into microbiome-based therapies and precision medicine offers promising opportunities for the market in the coming years.

Gastroenterology Market Segmentation

1. By Product Type

   • Pharmaceuticals (Proton Pump Inhibitors, Laxatives, Antacids, Biologics)

   • Medical Devices (Endoscopes, Capsule Endoscopy, GI Stents, Biopsy Forceps)

2. By Disease Type

   • Gastroesophageal Reflux Disease (GERD)

   • Irritable Bowel Syndrome (IBS)

   • Crohn’s Disease & Ulcerative Colitis

   • Colorectal Cancer

3. By End-User

   • Hospitals & Clinics

   • Ambulatory Surgical Centers

   • Research Institutes

4. By Region

   • North America

   • Europe

   • Asia-Pacific

   • Latin America

   • Middle East & Africa

Get a Free Sample Report with Table of Contents

Gastroenterology Market Growth

The gastroenterology market is projected to witness robust growth due to increasing global healthcare spending and the rising adoption of advanced diagnostic techniques. The development of AI-powered endoscopic imaging and robotic-assisted surgeries is enhancing the precision and efficiency of gastroenterological procedures. Additionally, the expansion of telemedicine and digital health solutions is facilitating remote consultations, making gastroenterology care more accessible. The introduction of novel drug formulations and personalized treatment approaches will further drive market expansion over the forecast period.

Recent Developments and Challenges in the Gastroenterology Market

1. Recent Developments:

   • The launch of AI-integrated endoscopy systems for early cancer detection and GI disease diagnosis.

   • Increased research on microbiome-targeted therapies for IBD and IBS.

   • The approval of new biologics and biosimilars for treating Crohn’s disease and ulcerative colitis.

   • Expanding clinical trials for novel GI therapeutics and drug delivery methods.

2. Challenges:

   • High costs associated with advanced gastroenterology procedures and biologic therapies.

   • Regulatory challenges and prolonged approval timelines for new drugs and medical devices.

   • A shortage of trained gastroenterologists in developing regions, limits access to specialized care.

   • Variability in patient response to gastrointestinal treatments complicates disease management strategies.

Key Players in the Gastroenterology Market

• Abbott Laboratories – A leading player in diagnostics and GI-related medical devices.

• Johnson & Johnson – Offers innovative GI treatments and medical devices for endoscopic procedures.

• AbbVie Inc. – Specializes in gastroenterology biologics, particularly for inflammatory bowel diseases.

• Salix Pharmaceuticals – Focuses on gastrointestinal disorder treatments and innovative drug formulations.

• GlaxoSmithKline Plc. – Develops a range of gastroenterology medications for acid reflux and ulcer treatments.

• ALLERGAN – Known for its portfolio of GI pharmaceuticals, including treatments for IBS.

• Takeda Pharmaceutical Company Limited – A leader in biologics for Crohn’s disease and ulcerative colitis.

• AstraZeneca – Specializes in acid-reducing drugs and GERD treatments.

• Astellas Pharma US, Inc. – Develops gastroenterology therapies and specialty pharmaceuticals.

• Pfizer Inc. – Offers a broad range of gastroenterology medications, including proton pump inhibitors and anti-inflammatory drugs.